Laurus Labs Limited

rs,

Laurus Labs Limited Corporate Office 2nd Floor, Serene Chambers, Road No. 7 Banjara Hills, Hyderabad- 50003Li, Telangana, India T +91 LiO 6659 Li333, 3980 Li333, 2

₹ 4,936

tor Presentation | April 28, 2022 FY22 – Overview Fairly Resilient operating metrics Revenues ₹ 4,936 Cr ▲3% EBITDA ₹ 1,436 Cr ▼ 9% Summary FY22 Consolidated Financials [₹Crore] Revenues Gross

3%

tion | April 28, 2022 FY22 – Overview Fairly Resilient operating metrics Revenues ₹ 4,936 Cr ▲3% EBITDA ₹ 1,436 Cr ▼ 9% Summary FY22 Consolidated Financials [₹Crore] Revenues Gross Margi

₹ 1,436

28, 2022 FY22 – Overview Fairly Resilient operating metrics Revenues ₹ 4,936 Cr ▲3% EBITDA ₹ 1,436 Cr ▼ 9% Summary FY22 Consolidated Financials [₹Crore] Revenues Gross Margins EBITDA % to Re

9%

2 – Overview Fairly Resilient operating metrics Revenues ₹ 4,936 Cr ▲3% EBITDA ₹ 1,436 Cr ▼ 9% Summary FY22 Consolidated Financials [₹Crore] Revenues Gross Margins EBITDA % to Revenues

55.6%

to Revenues Net Profit EPS Operating Cash flow Capex Net Debt-to-EBITDA ROCE FY22 4,936 55.6% 1,436 29.1% 828 15.4 FY22 911 950 1.15X 26.3% FY21 4,814 55.2% 1,573 32.7% 984 18.3

29.1%

Net Profit EPS Operating Cash flow Capex Net Debt-to-EBITDA ROCE FY22 4,936 55.6% 1,436 29.1% 828 15.4 FY22 911 950 1.15X 26.3% FY21 4,814 55.2% 1,573 32.7% 984 18.3 Y-o-Y 3% 4

1.15X

low Capex Net Debt-to-EBITDA ROCE FY22 4,936 55.6% 1,436 29.1% 828 15.4 FY22 911 950 1.15X 26.3% FY21 4,814 55.2% 1,573 32.7% 984 18.3 Y-o-Y 3% 40bps -9% -360bps -16% -16% FY

26.3%

pex Net Debt-to-EBITDA ROCE FY22 4,936 55.6% 1,436 29.1% 828 15.4 FY22 911 950 1.15X 26.3% FY21 4,814 55.2% 1,573 32.7% 984 18.3 Y-o-Y 3% 40bps -9% -360bps -16% -16% FY21 Y-o

55.2%

TDA ROCE FY22 4,936 55.6% 1,436 29.1% 828 15.4 FY22 911 950 1.15X 26.3% FY21 4,814 55.2% 1,573 32.7% 984 18.3 Y-o-Y 3% 40bps -9% -360bps -16% -16% FY21 Y-o-Y 733 700 0.89X

32.7%

22 4,936 55.6% 1,436 29.1% 828 15.4 FY22 911 950 1.15X 26.3% FY21 4,814 55.2% 1,573 32.7% 984 18.3 Y-o-Y 3% 40bps -9% -360bps -16% -16% FY21 Y-o-Y 733 700 0.89X 24% 36% 29%

40bps

% 828 15.4 FY22 911 950 1.15X 26.3% FY21 4,814 55.2% 1,573 32.7% 984 18.3 Y-o-Y 3% 40bps -9% -360bps -16% -16% FY21 Y-o-Y 733 700 0.89X 24% 36% 29% 45.1% -18.8%pts 5 Laurus

“Anticipate good growth in Other API Segment through FY23 supported by new contract supplies  Increased capacities by over 25% in FY22.”

“Chairman at Global Hospitals Group M M Key Qualification: MBBS and Masters in Surgery from Madras University, Fellowship of the UK Royal College of Surgeons FRCS(Glasg) & FRCS(Edin.) Key Expertise: Project Management, Strategy (ex- McKinsey & Co.), Risk mitigation Key Qualification: B.E from Osmania University, Master’s in Electrical and Computer Engineering from University of Illinois, PGP in Management from Indian School of Business C M Mrs.”

“UN has adopted a New 95-95-95 target for 2025  Progress Toward UNAIDS Targets on HIV Infection  New infections were significantly off-track from global goals.”

GROWTH PILLAR

4

GROWTH PILLAR

Integrated Approach Monetization of Pipeline assets Diversification into High Value therapies Revenue Growth Global Filings [₹ Cr] ▲ 14% Y-o-Y ▲ 32% Q-o-Q * Includes 11 Tentative approvals in US Key Highlights  FDF business recovered in Q4 with Revenues growing 14% YoY and 32% QoQ to ₹ 491 cr (34% of total revenues Vs. 30% last year)  Gradual stabilisation of ARV demand from Global Agencies is in line. Developed markets sales strong over FY21 led by portfolio expansion – Market share gains broadly stable  Laurus has signed up for MPP license for Pfizer anti-Covid pill Paxlovid to increase the broad access in LMIC markets  Progress on Capacity expansion: Brownfield capacity expansion at Unit 2 (to add 4bn units) is on track and expected to get commercialized by Q1FY23  Q4 & FY22 Global filings: 2 product dossiers were filed in Developed markets in Q4, taking total filings to 9 products for FY22 13 Laurus Q4 & Full Year 2022 Investor Presentation | April 28, 2022 430 521 495 373 491

GROWTH PILLAR

Process Chemistry & Cost Leadership Portfolio Expansion in High Value therapies Sizeable Capacity & Purpose built Facility Revenue Growth API Sales mix [₹ Cr] ▼ 32% Y-o-Y ▲ 27% Q-o-Q Key Highlights  API business growth bounced sequentially clocking 27% growth for the quarter at ₹ 539 cr (38% of total revenues vs. 56% last year)  ARV business saw healthy improvement in procurement during the quarter with revenue growing +47% QoQ. However, YoY decline remains steep -48% YoY due to high base effect of excess channel inventories. We remain optimistic about further recovery in ensuing quarters  Overall growth in Other APIs and Oncology Revenues was modest. Anticipate good growth in Other API Segment through FY23 supported by new contract supplies  Increased capacities by over 25% in FY22. Accelerating capacity expansion in select high growth therapeutics with Total reactor volume of +7000KL by the end of FY23 14 Laurus Q4 & Full Year 2022 Investor Presentation | April 28, 2022 262120397

GROWTH PILLAR

End-to-end Service Capability Built on IP Protection, Customer Flexibility Tremendous growth in outsourcing trend Revenue Growth Key Highlights [₹ Cr] ▲ 105% Y-o-Y ▲ 74% Q-o-Q Operational highlights Speed & Flexibility ◘ Customer base further diversified Excellent IP Protection Integrated Service Capability World Class Quality Standard ◘ +50 Projects handled across value chain ◘ New CDMO contract signed in FY22 ◘ Stepped up investment to enable customers globally via Capacity creation ◘ Four Commercial Stage Projects ◘ Four Big Pharma Clients ◘ 550KL+ dedicated capacity Self-Reliant subsidiary by FY2025 Build CDMO 5 manufacturing units by FY25 15 Laurus Q4 & Full Year 2022 Investor Presentation | April 28, 2022  Synthesis business maintained its robust growth momentum +105% YoY during the quarter to ₹ 360 cr. During full year FY22, CDMO business growth was solid at +77% (19% of total revenues vs. 11% last year)  Customer base further diversified, US, EU and Japan are still three most

GROWTH PILLAR

Opportunity in Recombinant AF Food Protein Synergize Biotech and fermentation capability Revenue Growth Pre-Acquisition Post [₹ Cr] New capacities continue to improve run-rate ▲ 289% Y-o-Y ▲ 40% Q-o-Q    Plan to create 1MN liters fermentation capacity Leveraging Parent’s existing Global Partnership and strong chemistry skills CDMO segment likely to be major growth contributor going ahead * Annualised basis Key Highlights  Revenues improved over 40% QoQ to ₹ 35cr fueled by new capacities getting operational  FY22 revenues improved materially by +70% over pre-acquisition annualized run-rate led by attractive market opportunities  Gradually ramping up on the 180KL fermentation capacity with our large scale CDMO partners. Full operational benefits of new capacities to reflect in FY23  Continue to work on Improving Products offering and Improving Go-to-market by leveraging relationship  In Process to acquire Additional land parcel with a plan to create close to 1 million liters ferm